{{drugbox
|drug = Vortioxetine
|tradenames = Brintellix
|synonyms = Lu-AA21004
|size = 200
|ChemSpider = 8141643
|DrugBank = None
|PubChem = 9966051
|formula = C18 H22 N2 S
|Mass = 298.4457 g/mol
|InChl = 1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
|InChl-key = YQNWZWMKLDQSAC-UHFFFAOYSA-N
|SMILES = CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
|jmol = http://chemapps.stolaf.edu/jmol/jmol.php?model=CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
|IUPAC = 1-{2-[(2,4-Dimethylphenyl)sulfanyl]phenyl}piperazine
}}
Vortioxetine is a multi-modal antidepressant that is solely approved for clinical use in the U.S.; it first received FDA approval in 30 September 2013.[1]
External links [ ]
Reference list [ ]
ν · τ · ε Antidepressants (ATC : N06A ) First-generation
TCAs
Amitriptyline ,
amoxapine ,
butriptyline ,
clomipramine ,
desipramine ,
dosulepin ,
doxepin ,
imipramine ,
maprotiline ,
nortriptyline ,
protriptyline ,
trimipramine
Second-generation